Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and Improve Frailty Outcomes

NCT ID: NCT07325305

Last Updated: 2026-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-17

Study Completion Date

2028-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a small trial testing out a new approach before doing a bigger study. Researchers are observing a group of children/adolescents (ages 5-17) with acute lymphoblastic leukemia (ALL) and testing a physical activity and exercise program on a group of them who after 5 weeks of treatment show signs of weakness or frailty.

Kids who are NOT losing muscle aren't part of the exercise trial - they're just monitored over time to see how they do.

The goal:

To see if an exercise program helps kids who are getting weaker from acute lymphoblastic leukemia treatment build back/maintain their strength, compared to kids who don't do the extra intervention. The study will also look at if this way of measuring muscle weakness works well for kids with cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot randomised controlled trial with a hybrid implementation design. At 5 weeks following an acute lymphoblastic leukaemia diagnosis children/adolescents (5-17 years) will be assessed for frailty using a novel frailty framework, to evaluate their frailty risk and identify those with signs of sarcopenia.

Children with signs of sarcopenia will be randomised to one of two groups:

1. Standard care only, or,
2. Physical activity and strengthening intervention plus activity tracking with a Fitbit (A wearable electronic activity tracker) This study will evaluate if the implementability of this intervention as well as the limited efficacy and investigate the framework for frailty used in this study.

It is known that children undergoing acute treatment for ALL experience signs of frailty from as early as 6 weeks post diagnosis. It is known that physical activity and exercise is safe and effective for children though it is most commonly conducted as a reactive therapy when children have already significantly deteriorated.

Very little is known regarding the pathophysiology that drives sarcopenia in children with cancer and there are no standardised diagnostic criteria, assessment tools or treatments. Often studies limit diagnosis to muscle ultrasound alone, omitting functional assessment. It has been recommended that a standardised criteria incorporating muscle mass (by ultrasound) and functional measurements (such as hand grip strength), should be established. This study aims to create a frailty framework including sarcopenia assessment ("muscle strength" and muscle mass "loss of muscle") as well as "slowness", "poor endurance", "low physical activity" as described in the outcome measurement section. This should contribute to a standardised criteria for sarcopenia as well as a criteria for identifying early signs of frailty with cut-offs.

The intervention aims to prevent frailty for participants with early signs of sarcopenia and currently there are no interventions that target frailty directly in children with cancer nor has frailty been investigated in the acute treatment phases of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Acute Lymphoblastic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Cohort observational study with embedded randomised control trial with randomisation 1:1 ratio to intervention and control group for those identified with sarcopenia after induction phase of treatment for acute lymphoblastic leukaemia.
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors
Due to the nature of the intervention the provider of the intervention will not be blinded and nor will the participant. The investigator will be blinded where possible and any unblinding will be recorded and reported.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation cohort

These participants did not have early signs of sarcopenia at the post induction therapy assessment point, but will be followed up at all timepoints to better understand the natural progression of acute lymphoblastic leukaemia.

Usual care is a ward based physiotherapist service which is reactive and referral based only.

Group Type NO_INTERVENTION

No interventions assigned to this group

Usual care control group

These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the control group. Usual care is a ward based physiotherapist service which is reactive and referral based only.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention group

These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the intervention group. The intervention group receives 9 weeks of goal setting and physical activity behaviour change coaching, as well as concurrently receiving 8 weeks of structured exercise sessions weekly (45-60 minutes per session x 3/week). These sessions are individualised based on the participant's functional performance outcomes from the assessment prior to randomisation, with a resistance strength training and progressive overload principles. The delivery of the specific exercises will be based on a pragmatic, participation based focus and will incorporate the individual's development stage, age, interests and enjoyment.

Group Type EXPERIMENTAL

Exercise

Intervention Type BEHAVIORAL

These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the intervention group. The intervention group receives 9 weeks of goal setting and physical activity behaviour change coaching (with activity tracking via Fitbit for continuous feedback) as well as concurrent 8 weeks of 3x45-60 minute structured exercise sessions weekly. These are individualised based on their functional performance outcomes from the assessment prior to randomisation with a resistance strength training and progressive overload principles. The delivery of the specific exercises will be based on a pragmatic, participation based focus and will incorporate the individuals development stage, age, interests and enjoyment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the intervention group. The intervention group receives 9 weeks of goal setting and physical activity behaviour change coaching (with activity tracking via Fitbit for continuous feedback) as well as concurrent 8 weeks of 3x45-60 minute structured exercise sessions weekly. These are individualised based on their functional performance outcomes from the assessment prior to randomisation with a resistance strength training and progressive overload principles. The delivery of the specific exercises will be based on a pragmatic, participation based focus and will incorporate the individuals development stage, age, interests and enjoyment.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

physical activity behaviour change wearable device

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 5-17 years at the time of consent
* New diagnosis of acute lymphoblastic leukaemia \<7 days
* Is planned to receive management for their cancer treatment at the trial site for the duration of the trial period
* Has a legally acceptable representative capable of understanding the informed consent document in English and providing consent on the participant's behalf
* Have a family electronic device that can be linked with the tool to be used (Fitbit)

Exclusion Criteria

* none
Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Murdoch Childrens Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rachel Conyers, A/Prof Paediatric Oncologist

Role: STUDY_DIRECTOR

Murdoch Children's Research Institute, Royal Children's Hospital (Melbourne), University of Melbourne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Children's Hospital

Melbourne, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarah Grimshaw, PhD Physiotherapy

Role: CONTACT

+61417162166

Ella Thorburn, Bachelor of Physiotherapy(hon)

Role: CONTACT

+61415066889

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sarah Grimshaw, PhD Physiotherapy

Role: primary

+61417162166

Ella Thorburn, Bachelor of Physiotherapy(hon)

Role: backup

+61415066889

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025/ETH01569

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.